Polycythaemia vera and JAK2 mutation

被引：0
|
作者：
P. M. Mannucci
机构：
[1] RCCS Maggiore Hospital Foundation and University of Milan,Department of Medicine and Medical Specialities
来源：
Internal and Emergency Medicine | 2007年 / 2卷
关键词：
Imatinib; Portal Hypertension; Oral Anticoagulant; Polycythemia Vera; Diabetic Ketoacidosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：147 / 147
相关论文
共 50 条
  • [21] JAK2 V617F mutation, cytogenetic abnormalities and endogenous erythroid colony formation in patients with polycythaemia vera
    Strnad, M.
    Zivanovic, B. Todoric
    Tarabar, O.
    Elez, M.
    Stamatovic, D.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1573 - 1573
  • [22] The JAK2 V617F point mutation correlates with clinical phenotype in patients with polycythaemia vera and essential thrombocythaemia
    Helbig, Grzegorz
    Wieczorkiewicz, Agata
    Krawczyk, Malgorzata
    Kata, Dariusz
    Seweryn, Marek
    Mendrek, Wlodzimierz
    Kopera, Malgorzata
    Stella-Holowiecka, Beata
    Krzemien, Slawomira
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2008, 12 (10): : 452 - 454
  • [23] Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera
    Scott, Linda M.
    Beer, Philip A.
    Bench, Anthony J.
    Erber, Wendy N.
    Green, Anthony R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (03) : 511 - 512
  • [24] JAK2 V617F MUTATION AND PRV-1 OVEREXPRESSION: RELEVANCE IN THE DIAGNOSIS OF POLYCYTHAEMIA VERA AND ESSENTIAL THROMBOCYTHAEMIA
    Melis, S.
    Vellinga, S.
    Zachee, P.
    Sierens, A. C.
    De Schouwer, P. J. J. C.
    ACTA CLINICA BELGICA, 2009, 64 (05) : 429 - 433
  • [25] Evaluation of Jak2 exon 12 mutation in patients with polycythemia vera
    Asad, Fatemeh Zadeh
    Saki, Najmaldin
    Asl, Javad Mohammadi
    Vosoughi, Tina
    Asadi, Zari Tahannejad
    CLINICAL CANCER INVESTIGATION JOURNAL, 2020, 9 (06): : 244 - 248
  • [26] The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera
    D Olcaydu
    R C Skoda
    R Looser
    S Li
    M Cazzola
    D Pietra
    F Passamonti
    E Lippert
    S Carillo
    F Girodon
    A Vannucchi
    N S Reading
    J T Prchal
    C Ay
    I Pabinger
    H Gisslinger
    R Kralovics
    Leukemia, 2009, 23 : 1924 - 1926
  • [27] The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera
    Olcaydu, D.
    Skoda, R. C.
    Looser, R.
    Li, S.
    Cazzola, M.
    Pietra, D.
    Passamonti, F.
    Lippert, E.
    Carillo, S.
    Girodon, F.
    Vannucchi, A.
    Reading, N. S.
    Prchal, J. T.
    Ay, C.
    Pabinger, I.
    Gisslinger, H.
    Kralovics, R.
    LEUKEMIA, 2009, 23 (10) : 1924 - 1926
  • [28] The JAK2 mutation
    Merchant, Salma
    CELLULAR AND MOLECULAR ASPECTS OF MYELOPROLIFERATIVE NEOPLASMS - PT A, 2021, 365 : 117 - 162
  • [29] MINOCA as the first presentation of JAK2 V617F-positive polycythaemia rubra vera
    Rus, M. R. Mohamed
    Suhaimi, A. Mohd
    Zulkufli, M. R.
    Kassim, N. Mohd
    Rozali, N.
    Hussin, F. R.
    Shahril, N. S.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 369 : 41 - 41
  • [30] Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients
    C M Butcher
    U Hahn
    L B To
    J Gecz
    E J Wilkins
    H S Scott
    P G Bardy
    R J D'Andrea
    Leukemia, 2008, 22 : 870 - 873
12345